Results 311 to 320 of about 268,746 (338)
Some of the next articles are maybe not open access.
Immune checkpoint inhibitors and vasculitis
Current Opinion in Rheumatology, 2020Purpose of review Clinical use of immune checkpoint inhibitor (ICI) therapy has revolutionized the therapeutic landscape of cancer. By activating the immune system using monoclonal anti-CTLA-4 and PD(L)-1 antibodies, remission can be induced in previously terminal cancers. However, these breakthroughs come at a price.
Patrick, Boland +2 more
openaire +2 more sources
Immune Checkpoint Inhibitors–Related Cardiotoxicity
American Journal of Therapeutics, 2020Background: Immunotherapy is a significant breakthrough in cancer therapy in the last decade. Immunotherapy is better tolerated compared with chemotherapy. However, it does have side effects, and one of the rare and serious side effects of immunotherapy is cardiotoxicity.
Venu Madhav, Konala +2 more
openaire +2 more sources
Immune Checkpoint Inhibitors-Induced Colitis
2018Immune checkpoint inhibitors (ICIs) have shown significant benefit in cancer patients, but are associated with immune-related adverse events (irAEs), that can affect the gastrointestinal tract resulting in diarrhea and colitis. IrAEs range from mild self-limiting to severe life-threatening disease, which potentially limit the use of these medications ...
Yun, Tian +2 more
openaire +2 more sources
Cervical cancer prevention and control in women living with human immunodeficiency virus
Ca-A Cancer Journal for Clinicians, 2021Philip E Castle, Vikrant V Sahasrabuddhe
exaly
A review of cancer immunotherapy toxicity
Ca-A Cancer Journal for Clinicians, 2020Lucy Boyce Kennedy
exaly
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Ca-A Cancer Journal for Clinicians, 2020Vaibhav G Patel +2 more
exaly